North America continues to employ AI for diagnostic purposes, thanks to an emphasis on innovation and technical developments.” Avant Technologies, Inc.(OTCQB: AVAI) Partner, Ainnova, Signs Pilot Program with Roche to Combat Diabetic Retinopathy- Avant Technologies, Inc.("Avant” or the "Company”), partner, Ainnova Tech, Inc., (Ainnova) a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that the company has entered into a strategic alliance with global biotech, Roche, and leading pre-paid health plan provider, Salud 360, to begin a pilot program to combat diabetic retinopathy using Ainnova’s cutting-edge technology.
"With more than 10 clinical and preclinical programs in the internal pipeline, more than 10 partnered programs and over $450M in upfront and realized milestone payments received from partners to date out of more than $20B possible, we are advancing a flywheel of discovery and creating value in our pipeline through technology.” Tempus AI, Inc.(NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, recently announced the collaboration with Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point of care solutions in oncology, to integrate its comprehensive genomic testing directly into Flatiron’s cloud-based Electronic Medical Record (EMR) platform, OncoEMR® through the Molecular Profiling Integration (MPI).
Today, we are starting with diabetic retinopathy, but the vision is that we can eventually multiply this same effort for other critical diseases that require innovative solutions.” CONTINUED… Read this and more news for Avant Technologies at: In other healthcare/technology industry developments and happenings in the market recently include: Roche (OTCQX: RHHBY) recently announced that it has entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc.(PSTX), a public clinical-stage biopharmaceutical company pioneering donor-derived CAR-T cell therapies.
The story "Artificial Intelligence (AI) Redefining Medical Diagnostics Industry That’s Expected to be a $7.2 Billion Market by 2029" has 2045 words across 67 sentences, which will take approximately 9 - 18 minutes for the average person to read.
Which news outlet covered this story?
The story "Artificial Intelligence (AI) Redefining Medical Diagnostics Industry That’s Expected to be a $7.2 Billion Market by 2029" was covered 2 weeks ago by GlobeNewswire, a news publisher based in China.
How trustworthy is 'GlobeNewswire' news outlet?
GlobeNewswire is a fully independent (privately-owned) news outlet established in 1998 that covers mostly technology news.
The outlet is headquartered in China and publishes an average of 7 news stories per day.
It's most recent story was published 12 hours ago.
What do people currently think of this news story?
The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.
How do I report this news for inaccuracy?
You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
